A dietary supplement containing cinnamon, chromium and carnosine decreases fasting plasma glucose and increases lean mass in overweight or obese pre-diabetic subjects: A randomized, placebo-controlled trial

PLoS ONE

Volumn 10, Issue 9, 2015, Pages

  Liu, Yuejun ^a,b,c   Cotillard, Aurélie ^a,b,c   Vatier, Camille ^a,b,g   Bastard, Jean Philippe ^a,d   Fellahi, Soraya ^a,d   Stévant, Marie ^e   Allatif, Omran ^a,b   Langlois, Clotilde ^f   Bieuvelet, Séverine ^e   Brochot, Amandine ^f   Guilbot, Angèle ^f   Clément, Karine ^a,b,c   Rizkalla, Salwa W ^a,b,c  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b Institute OfCardiometabolism and Nutrition   (France)

^c SORBONNE UNIVERSITÉ   (France)

^d HÔPITAL TENON   (France)

^e AdipoPhYt   (France)

^f Groupe PiLeJe   (France)

^g CENTRE DE RECHERCHE SAINT ANTOINE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CARNOSINE; CHROMIUM; CINNAMON EXTRACT; GLUCOSE; INSULIN; PLACEBO; GLUCOSE BLOOD LEVEL; PLANT EXTRACT;

ADULT; AGED; ARTICLE; CALORIC INTAKE; CINNAMON; CONTROLLED STUDY; DIABETES MELLITUS; DIET; DIET SUPPLEMENTATION; DOUBLE BLIND PROCEDURE; FAT FREE MASS; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INFLAMMATION; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; LEAN BODY WEIGHT; MACRONUTRIENT; MAJOR CLINICAL STUDY; MALE; OBESITY; OUTCOME ASSESSMENT; PHYSICAL ACTIVITY; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; ANATOMY AND HISTOLOGY; BLOOD; BODY COMPOSITION; CHEMISTRY; CINNAMOMUM ZEYLANICUM; COMPLICATION; DIABETES MELLITUS, TYPE 2; DIET RESTRICTION; DIET THERAPY; DIETARY SUPPLEMENT; DRUG EFFECTS; METABOLISM; MIDDLE AGED; MUSCLE;

ADULT; AGED; BLOOD GLUCOSE; BODY COMPOSITION; CARNOSINE; CHROMIUM; CINNAMOMUM ZEYLANICUM; DIABETES MELLITUS, TYPE 2; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; FASTING; FEMALE; HUMANS; MALE; MIDDLE AGED; MUSCLES; OBESITY; OVERWEIGHT; PLACEBOS; PLANT EXTRACTS; PREDIABETIC STATE;

EID: 84947733215     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0138646     Document Type: Article

References (78)

1. International Diabetes Federation. IDF Diabetes Atlas, 6th edn. Brussels, Belgium: International Diabetes Federation. http://www.idf.org/diabetesatlas. 2013.
2. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2010; 33 Suppl 1: S62-9. doi: 10.2337/dc10-S062 PMID: 20042775
3. American Diabetes Association Standard of medical care in diabetes. Diabetes Care. 2014; 37 Suppl 1: S14-80. doi: 10.2337/dc14-S014 PMID: 24357209
4. Ryden L, Grant PJ, Anker SD, Berne C, Cosentino F, Danchin N, et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J. 2013; 34(39):3035-87. doi: 10.1093/eurheartj/eht108 PMID: 23996285
5. Garber AJ, Handelsman Y, Einhorn D, Bergman DA, Bloomgarden ZT, Fonseca V, et al. Diagnosis and management of prediabetes in the continuum of hyperglycemia: when do the risks of diabetes begin? A consensus statement from the American College of Endocrinology and the American Association of Clinical Endocrinologists. Endocr Pract. 2008; 14(7):933-46. PMID: 18996826
6. Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, et al. American Association of Clinical Endocrinologists' comprehensive diabetes management algorithm 2013 consensus statement-executive summary. Endocr Pract. 2013; 19(3):536-57. doi: 10.4158/EP13176.CS PMID: 23816937
7. Tabak AG, Herder C, Rathmann W, Brunner EJ, Kivimaki M. Prediabetes: a high-risk state for diabetes development. Lancet. 2012; 379(9833):2279-90. doi: 10.1016/S0140-6736(12)60283-9 PMID: 22683128
8. Moutzouri E, Tsimihodimos V, Rizos E, Elisaf M. Prediabetes: to treat or not to treat? Eur J Pharmacol. 2011; 672(1-3):9-19. doi: 10.1016/j.ejphar.2011.10.007 PMID: 22020287
9. Portero McLellan KC, Wyne K, Villagomez ET, Hsueh WA. Therapeutic interventions to reduce the risk of progression from prediabetes to type 2 diabetes mellitus. Ther Clin Risk Manag. 2014; 10:173-88. doi: 10.2147/TCRM.S39564 PMID: 24672242
10. Paulweber B, Valensi P, Lindstrom J, Lalic NM, Greaves CJ, McKee M, et al. A European evidencebased guideline for the prevention of type 2 diabetes. Horm Metab Res. 2010; 42 Suppl 1:S3-36. doi: 10.1055/s-0029-1240928 PMID: 20391306
11. Qin B, Nagasaki M, Ren M, Bajotto G, Oshida Y, Sato Y. Cinnamon extract (traditional herb) potentiates in vivo insulin-regulated glucose utilization via enhancing insulin signaling in rats. Diabetes Res Clin Pract. 2003; 62(3):139-48. PMID: 14625128
12. Qin B, Dawson H, Polansky MM, Anderson RA. Cinnamon extract attenuates TNF-alpha-induced intestinal lipoprotein ApoB48 overproduction by regulating inflammatory, insulin, and lipoprotein pathways in enterocytes. Horm Metab Res. 2009; 41(7):516-22. PMID: 19593846
13. Qin B, Nagasaki M, Ren M, Bajotto G, Oshida Y, Sato Y. Cinnamon extract prevents the insulin resistance induced by a high-fructose diet. Horm Metab Res. 2004; 36(2):119-25. PMID: 15002064
14. Sheng X, Zhang Y, Gong Z, Huang C, Zang YQ. Improved Insulin Resistance and Lipid Metabolism by Cinnamon Extract through Activation of Peroxisome Proliferator-Activated Receptors. PPAR Res. 2008; 2008:581348. doi: 10.1155/2008/581348 PMID: 19096709
15. Khan A, Safdar M, li Khan MM, Khattak KN, Anderson RA. Cinnamon improves glucose and lipids of people with type 2 diabetes. Diabetes Care. 2003; 26(12):3215-8. PMID: 14633804
16. Rafehi H, Ververis K, Karagiannis TC. Controversies surrounding the clinical potential of cinnamon for the management of diabetes. Diabetes Obes Metab. 2012; 14(6):493-9. doi: 10.1111/j.1463-1326. 2011.01538.x PMID: 22093965
17. Leach MJ, Kumar S. Cinnamon for diabetes mellitus. Cochrane Database Syst Rev. 2012; 9: CD007170. doi: 10.1002/14651858.CD007170.pub2 PMID: 22972104
18. Akilen R, Tsiami A, Devendra D, Robinson N. Cinnamon in glycaemic control: Systematic review and meta analysis. Clin Nutr. 2012; 31(5):609-15. doi: 10.1016/j.clnu.2012.04.003 PMID: 22579946
19. Allen RW, Schwartzman E, Baker WL, Coleman CI, Phung OJ. Cinnamon use in type 2 diabetes: an updated systematic review and meta-analysis. Ann Fam Med. 2013; 11(5):452-9. doi: 10.1370/afm. 1517 PMID: 24019277
20. Davis PA, YokoyamaW. Cinnamon intake lowers fasting blood glucose: meta-analysis. J Med Food. 2011; 14(9):884-9. doi: 10.1089/jmf.2010.0180 PMID: 21480806
21. Ziegenfuss TN, Hofheins JE, Mendel RW, Landis J, Anderson RA. Effects of a water-soluble cinnamon extract on body composition and features of the metabolic syndrome in pre-diabetic men and women. J Int Soc Sports Nutr. 2006; 3:45-53. doi: 10.1186/1550-2783-3-2-45 PMID: 18500972
22. Roussel AM, Hininger I, Benaraba R, Ziegenfuss TN, Anderson RA. Antioxidant effects of a cinnamon extract in people with impaired fasting glucose that are overweight or obese. J Am Coll Nutr. 2009; 28 (1):16-21. PMID: 19571155
23. Balk EM, Tatsioni A, Lichtenstein AH, Lau J, Pittas AG. Effect of chromium supplementation on glucose metabolism and lipids: a systematic review of randomized controlled trials. Diabetes Care. 2007; 30 (8):2154-63. PMID: 17519436
24. Pittler MH, Stevinson C, Ernst E. Chromium picolinate for reducing body weight: meta-analysis of randomized trials. Int J Obes Relat Metab Disord. 2003; 27(4):522-9. PMID: 12664086
25. Martin J, Wang ZQ, Zhang XH, Wachtel D, Volaufova J, Matthews DE, et al. Chromium picolinate supplementation attenuates body weight gain and increases insulin sensitivity in subjects with type 2 diabetes. Diabetes Care. 2006; 29(8):1826-32. PMID: 16873787
26. Reddy VP, Garrett MR, Perry G, Smith MA. Carnosine: a versatile antioxidant and antiglycating agent. Sci Aging Knowledge Environ. 2005; 2005(18):e12.
27. Anderson RA. Effects of chromium on body composition and weight loss. Nutr Rev. 1998; 56(9):266-70. PMID: 9763876
28. Rizkalla SW, Prifti E, Cotillard A, Pelloux V, Rouault C, Allouche R, et al. Differential effects of macronutrient content in 2 energy-restricted diets on cardiovascular risk factors and adipose tissue cell size in moderately obese individuals: a randomized controlled trial. Am J Clin Nutr. 2012; 95(1):49-63. doi: 10.3945/ajcn.111.017277 PMID: 22170375
29. Pellegrinelli V, Rouault C, Veyrie N, Clement K, Lacasa D. Endothelial cells from visceral adipose tissue disrupt adipocyte functions in a three-dimensional setting: partial rescue by angiopoietin-1. Diabetes. 2014; 63(2):535-49. doi: 10.2337/db13-0537 PMID: 24130331
30. Ribiere C, Jaubert AM, Sabourault D, Lacasa D, Giudicelli Y. Insulin stimulates nitric oxide production in rat adipocytes. Biochem Biophys Res Commun. 2002; 291(2):394-9. PMID: 11846418
31. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985; 28(7):412-9. PMID: 3899825
32. Antuna-Puente B, Disse E, Faraj M, Lavoie ME, Laville M, Rabasa-Lhoret R, et al. Evaluation of insulin sensitivity with a new lipid-based index in non-diabetic postmenopausal overweight and obese women before and after a weight loss intervention. Eur J Endocrinol. 2009; 161(1):51-6. doi: 10.1530/EJE-09-0091 PMID: 19429699
33. Stunkard AJ, Messick S. The three-factor eating questionnaire to measure dietary restraint, disinhibition and hunger. J Psychosom Res. 1985; 29(1):71-83. PMID: 3981480
34. Baecke JA, Burema J, Frijters JE. A short questionnaire for the measurement of habitual physical activity in epidemiological studies. Am J Clin Nutr. 1982; 36(5):936-42. PMID: 7137077
35. Lemon J. Plotrix: a package in the red light district of R. R-News. 2006; 6(4):8-12.
36. Pinheiro J, Bates D, DebRoy S, Sarkar D. R Development Core Team. nlme: Linear and Nonlinear Mixed Effects Models. R package version 3.1-103. Vienna: R Foundation for Statistical Computing. 2012.
37. Onakpoya I, Posadzki P, Ernst E. Chromium supplementation in overweight and obesity: a systematic review and meta-analysis of randomized clinical trials. Obes Rev. 2013; 14(6):496-507. doi: 10.1111/obr.12026 PMID: 23495911
38. Bailey CH. Improved meta-analytic methods show no effect of chromium supplements on fasting glucose. Biol Trace Elem Res. 2014; 157(1):1-8. doi: 10.1007/s12011-013-9863-9 PMID: 24293356
39. Kleefstra N, Houweling ST, Bilo HJ. Effect of chromium supplementation on glucose metabolism and lipids: a systematic review of randomized controlled trials. Diabetes Care. 2007; 30(9):e102. PMID: 17726181
40. Evert AB, Boucher JL, Cypress M, Dunbar SA, Franz MJ, Mayer-Davis EJ, et al. Nutrition therapy recommendations for the management of adults with diabetes. Diabetes Care. 2014; 37 Suppl 1:S120-S143. doi: 10.2337/dc14-S120 PMID: 24357208
41. Anderson RA, Broadhurst CL, Polansky MM, Schmidt WF, Khan A, Flanagan VP, et al. Isolation and characterization of polyphenol type-A polymers from cinnamon with insulin-like biological activity. J Agric Food Chem. 2004; 52(1):65-70. PMID: 14709014
42. Ranasinghe P, Jayawardana R, Galappaththy P, Constantine GR, de Vas GN, Katulanda P. Efficacy and safety of 'true' cinnamon (Cinnamomum zeylanicum) as a pharmaceutical agent in diabetes: a systematic review and meta-analysis. Diabet Med. 2012; 29(12):1480-92. doi: 10.1111/j.1464-5491.2012. 03718.x PMID: 22671971
43. Ranasinghe P, Perera S, Gunatilake M, Abeywardene E, Gunapala N, Premakumara S, et al. Effects of Cinnamomum zeylanicum (Ceylon cinnamon) on blood glucose and lipids in a diabetic and healthy rat model. Pharmacognosy Res. 2012; 4(2):73-9. doi: 10.4103/0974-8490.94719 PMID: 22518078
44. European Food Safety Authority (EFSA). Scientific Opinion of the Panel on Food Additives, Flavourings, Processing Aids and Materials in Contact with Food on a request from the European Commission on Coumarin in flavourings and other food ingredients with flavouring properties. 2008. Report No.: 793.
45. Ranasinghe P, Pigera S, Premakumara GA, Galappaththy P, Constantine GR, Katulanda P. Medicinal properties of 'true' cinnamon (Cinnamomum zeylanicum): a systematic review. BMC Complement Altern Med. 2013; 13:275. doi: 10.1186/1472-6882-13-275 PMID: 24148965
46. Crawford P. Effectiveness of cinnamon for lowering hemoglobin A1C in patients with type 2 diabetes: a randomized, controlled trial. J Am Board Fam Med. 2009; 22(5):507-12. doi: 10.3122/jabfm.2009.05. 080093 PMID: 19734396
47. Akilen R, Tsiami A, Devendra D, Robinson N. Glycated haemoglobin and blood pressure-lowering effect of cinnamon in multi-ethnic Type 2 diabetic patients in the UK: a randomized, placebo-controlled, double-blind clinical trial. Diabet Med. 2010; 27(10):1159-67. doi: 10.1111/j.1464-5491.2010.03079.x PMID: 20854384
48. Mang B, Wolters M, Schmitt B, Kelb K, Lichtinghagen R, Stichtenoth DO, et al. Effects of a cinnamon extract on plasma glucose, HbA, and serum lipids in diabetes mellitus type 2. Eur J Clin Invest. 2006; 36(5):340-4. PMID: 16634838
49. Incani M, Sentinelli F, Perra L, Pani MG, Porcu M, Lenzi A, et al. Glycated hemoglobin for the diagnosis of diabetes and prediabetes: Diagnostic impact on obese and lean subjects, and phenotypic characterization. J Diabetes Investig. 2015; 6(1):44-50. doi: 10.1111/jdi.12241 PMID: 25621132
50. Medagama AB, Bandara R, Abeysekera RA, Imbulpitiya B, Pushpakumari T. Use of Complementary and Alternative Medicines (CAMs) among type 2 diabetes patients in Sri Lanka: a cross sectional survey. BMC Complement Altern Med. 2014; 14:374. doi: 10.1186/1472-6882-14-374 PMID: 25280877
51. Pan XR, Li GW, Hu YH, Wang JX, Yang WY, An ZX, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care. 1997; 20(4):537-44. PMID: 9096977
52. Li G, Zhang P, Wang J, Gregg EW, Yang W, Gong Q, et al. The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study. Lancet. 2008; 371(9626):1783-9. doi: 10.1016/S0140-6736(08)60766-7 PMID: 18502303
53. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001; 344(18):1343-50. PMID: 11333990
54. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002; 346(6):393-403. PMID: 11832527
55. Gerstein HC, Yusuf S, Bosch J, Pogue J, Sheridan P, Dinccag N, et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet. 2006; 368(9541):1096-105. PMID: 16997664
56. DeFronzo RA, Tripathy D, Schwenke DC, Banerji M, Bray GA, Buchanan TA, et al. Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med. 2011; 364(12):1104-15. doi: 10.1056/NEJMoa1010949 PMID: 21428766
57. Heine RJ, Diamant M, Mbanya JC, Nathan DM. Management of hyperglycaemia in type 2 diabetes: the end of recurrent failure? BMJ. 2006; 333(7580):1200-4. PMID: 17158386
58. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000; 321(7258):405-12. PMID: 10938048
59. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998; 339(4):229-34. PMID: 9673301
60. Bragg F, Li L, Smith M, Guo Y, Chen Y, Millwood I, et al. Associations of blood glucose and prevalent diabetes with risk of cardiovascular disease in 500 000 adult Chinese: the China Kadoorie Biobank. Diabet Med. 2014; 31(5):540-51. doi: 10.1111/dme.12392 PMID: 24344928
61. Gerstein HC, Punthakee Z. Dysglycemia and the Risk of Cardiovascular Events. Evidence-Based Cardiology. Wiley-Blackwell; 2009. p. 179-89.
62. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet. 2002 Jun 15; 359(9323):2072-7. PMID: 12086760
63. Vafa M, Mohammadi F, Shidfar F, Sormaghi MS, Heidari I, Golestan B, et al. Effects of cinnamon consumption on glycemic status, lipid profile and body composition in type 2 diabetic patients. Int J Prev Med. 2012; 3(8):531-6. PMID: 22973482
64. Miller CT, Fraser SF, Levinger I, Straznicky NE, Dixon JB, Reynolds J, et al. The effects of exercise training in addition to energy restriction on functional capacities and body composition in obese adults during weight loss: a systematic review. PLoS One. 2013; 8(11):e81692. doi: 10.1371/journal.pone. 0081692 PMID: 24409219
65. Srikanthan P, Hevener AL, Karlamangla AS. Sarcopenia exacerbates obesity-associated insulin resistance and dysglycemia: findings from the National Health and Nutrition Examination Survey III. PLoS One. 2010; 5(5):e10805. doi: 10.1371/journal.pone.0010805 PMID: 22421977
66. Dominguez LJ, Barbagallo M. The cardiometabolic syndrome and sarcopenic obesity in older persons. J Cardiometab Syndr. 2007; 2(3):183-9. PMID: 17786082
67. Atlantis E, Martin SA, Haren MT, Taylor AW, Wittert GA. Inverse associations between muscle mass, strength, and the metabolic syndrome. Metabolism. 2009; 58(7):1013-22. doi: 10.1016/j.metabol.2009. 02.027 PMID: 19394973
68. Martins AR, Nachbar RT, Gorjao R, Vinolo MA, Festuccia WT, Lambertucci RH, et al. Mechanisms underlying skeletal muscle insulin resistance induced by fatty acids: importance of the mitochondrial function. Lipids Health Dis. 2012; 11:30. doi: 10.1186/1476-511X-11-30 PMID: 22360800
69. Theuma P, Fonseca VA. Inflammation, insulin resistance, and atherosclerosis. Metab Syndr Relat Disord. 2004; 2(2):105-13. doi: 10.1089/met.2004.2.105 PMID: 18370641
70. Haffner SM. Insulin resistance, inflammation, and the prediabetic state. Am J Cardiol. 2003; 92 (4A):18J-26J. PMID: 12957323
71. Festa A, Hanley AJ, Tracy RP, D'Agostino R Jr., Haffner SM. Inflammation in the prediabetic state is related to increased insulin resistance rather than decreased insulin secretion. Circulation. 2003; 108 (15):1822-30. PMID: 14517163
72. Lu Q, Tong N, Liu Y, Li N, Tang X, Zhao J, et al. Community-based population data indicates the significant alterations of insulin resistance, chronic inflammation and urine ACR in IFG combined IGT group among prediabetic population. Diabetes Res Clin Pract. 2009; 84(3):319-24. doi: 10.1016/j.diabres. 2009.03.002 PMID: 19442860
73. Suksomboon N, Poolsup N, Yuwanakorn A. Systematic review and meta-analysis of the efficacy and safety of chromium supplementation in diabetes. J Clin Pharm Ther. 2014; 39(3):292-306. doi: 10.1111/jcpt.12147 PMID: 24635480
74. Abdollahi M, Farshchi A, Nikfar S, Seyedifar M. Effect of chromium on glucose and lipid profiles in patients with type 2 diabetes; a meta-analysis review of randomized trials. J Pharm Pharm Sci. 2013; 16(1):99-114. PMID: 23683609
75. Crawford V, Scheckenbach R, Preuss HG. Effects of niacin-bound chromium supplementation on body composition in overweight African-American women. Diabetes Obes Metab. 1999; 1(6):331-7. PMID: 11225649
76. Kim CW, Kim BT, Park KH, Kim KM, Lee DJ, Yang SW, et al. Effects of short-term chromium supplementation on insulin sensitivity and body composition in overweight children: randomized, double-blind, placebo-controlled study. J Nutr Biochem. 2011; 22(11):1030-4. doi: 10.1016/j.jnutbio.2010.10.001 PMID: 21216583
77. Nagai K, Niijima A, Yamano T, Otani H, Okumra N, Tsuruoka N, et al. Possible role of L-carnosine in the regulation of blood glucose through controlling autonomic nerves. Exp Biol Med (Maywood). 2003; 228(10):1138-45.
78. Nagai K, Tanida M, Niijima A, Tsuruoka N, Kiso Y, Horii Y, et al. Role of L-carnosine in the control of blood glucose, blood pressure, thermogenesis, and lipolysis by autonomic nerves in rats: involvement of the circadian clock and histamine. Amino Acids. 2012; 43(1):97-109. doi: 10.1007/s00726-012-1251-9 PMID: 22367578